Randomized Comparison of Mobilization Kinetics of Circulating CD34+ Cells Between Biweekly CHOP and Dose-Escalated CHOP with the Prophylactic Use of Lenograstim (Glycosylated rHuG-CSF) in Aggressive Non-Hodgkin's Lymphoma

• Published in: Leukemia & lymphoma Vol. 38; no. 5-6; pp. 521 - 532
• Main Authors: Itoh, Kuniaki, Ohtsu, Tomoko, Sasaki, Yasutsuna, Ogura, Michinori, Morishima, Yasuo, Kasai, Masaharu, Chou, Takaaki, Yoshida, Kouki, Ohno, Tatsuharu, Mizorogi, Fumi, Uike, Naokuni, Sai, Toshiaki, Taniwakf, Masafumi, Ikeda, Shuichi, Tobinai, Kensei
• Format: Journal Article
• Language: English
• Published: Informa UK Ltd 2000; Taylor & Francis
• Subjects: CD34 antigen; CD34+ cells; CHOP; cyclophosphamide; G-CSF; lenograstim; non-Hodgkin's lymphoma
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428190009059271

High-dose chemotherapy with autologous hematopoietic stem cell transplantation has been expected to result in a promising outcome in high risk aggressive non- Hodgkin's lymphoma (NHL). However, it remains unknown what type of initial chemotherapy is optimal, especially regarding progenitor cell mobilization. Sixty-three untreated patients with aggressive NHL in a high risk group were randomized to either a biweekly arm with 8 cycles of standard CHOP or 6 cycles of the dose-escalated CHOP arm with cyclophosphamide 1.5 g/m2 and doxorubicin 70 mg/m2. Lenograstim (glycosylated rHuG-CSF 2.0 µg/kg/day) was administered daily from day 3 to patients in both arms. The mobilization effect of the two regimens on circulating CD34+ cells was evaluated. Twenty-seven of 29 patients in the biweekly CHOP arm and 33 of 34 patients in the dose-escalated CHOP were assessable. Dose-escalated CHOP yielded a significantly higher number of circulating CD34+ cells in the first cycle compared with biweekly CHOP (p=0.05). The peak number of circulating CD34+ cells with biweekly CHOP did not significantly change from cycle to cycle; however, in dose-escalated CHOP, the peak number of circulating CD34+ cells mobilized after the fifth and sixth cycle was lower than after the first cycle (p=0.07 and 0.009, respectively). Routine conventional-dose chemotherapy and low-dose G-CSF can mobilize sufficient CD34+ cells in patients with aggressive NHL. The mobilization kinetics of circulating progenitor cells in patients with aggressive NHL is dependent on the dosage and schedule of CHOP.